|
Mountain View, California (September 3, 2002) - SurroMed, Inc. today
announced that it has entered into a pilot biomarker discovery
collaboration with Eli Lilly and Company (NYSE: LLY). Under the
terms of the agreement, Lilly will supply preclinical samples for
analysis in SurroMed’s Biomarker Discovery Laboratory using its
proprietary, integrated mass spectrometry based platform for proteomic
and small organic molecule analysis in order to identify candidate
biomarkers of disease. Financial terms of the agreement were not disclosed.
"We are delighted to have the opportunity to collaborate
with Lilly, " said Gordon Ringold, Ph.D., CEO and Chairman
of SurroMed. "Our quantitative differential protein and small
organic molecule profiling capabilities provide a unique combination
of sensitivity, throughput and reproducibility that enable rapid and
effective biomarker identification."
SurroMed’s integrated biomarker discovery program combines proprietary
sample preparation techniques with advanced high-resolution mass spectrometric
methods for the differential analysis of biological samples. Subsequently,
detailed bioanalytical data is analyzed and mined using SurroMed’s suite of
informatics tools. Biomarker analysis and profiling has multiple applications
across all stages of the drug discovery and development continuum from preclinical
analysis of animal samples to follow-up evaluation of patients already receiving
marketed products.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed is pioneering biomarker
enabled drug discovery and development. The company focuses on discovering
and applying biomarkers to improve the drug discovery and development process
and enable the precise diagnosis and personalized treatment of disease. SurroMed’s
research process yields biological markers and information that enable accelerated,
cost-efficient discovery and development of new therapeutic products, as well as
development of diagnostic tests for early disease detection, disease staging, patient
stratification, and guiding and monitoring therapy.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1961
email: [email protected]
Noonan/Russo Communications, Inc.
Ian R. McConnell
Senior Account Executive
415) 677-4455 ext. 233
email: [email protected]
|
